Genmab and seagen present data from tisotumab vedotin (tivdak®) clinical development program and additional cervical cancer research at asco 2022 annual meeting

Copenhagen, denmark & bothell, wash.--(business wire)--genmab a/s (nasdaq: gmab) and seagen inc. (nasdaq: sgen) today announced interim data from the innovatv 205 trial, which included data evaluating tisotumab vedotin (tivdak®) in combination with pembrolizumab (cohort e) in patients with recurrent or metastatic cervical cancer (r/mcc) who have not received prior systemic therapy, with a confirmed objective response rate (orr) of 41% (95% confidence interval [ci]: 24% to 59%) and median durabi
SGEN Ratings Summary
SGEN Quant Ranking